Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06391619
Other study ID # 145646
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date April 6, 2022
Est. completion date December 1, 2025

Study information

Verified date April 2024
Source University College, London
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to learn about the first signs of disease in young adult carriers of the gene for Huntington's disease. The main questions to answer are: - what are the earliest signs of the disease? - can we identify the best time to intervene with treatment to prevent or delay onset of symptoms? - can we identify the most reliable markers of disease for use in prevention trials? Participants will undergo the following assessments: - clinical examination - cognitive and neuropsychiatric testing - brain imaging - biofluid sampling Researchers will compare gene carriers with matched controls to see if any of these measures show evidence of early disease effects.


Description:

We will undertake follow up assessments of the HD-YAS cohort comprising far-from-onset premanifest mutation carriers (preHD) (n=64) and controls, matched for age, sex and education (n=67). These assessments will occur approximately 4.5 and 6 years after their baseline assessment. They will include - detailed clinical assessment - cognitive testing using CANTAB and the EMOTICOM - neuropsychiatric assessment - neuroimaging including 3T volumetric MRI, NODDI, resting state fMRI and multiparametric mapping. A subset of 20 gene carriers and 20 controls will undergo 7T imaging - blood and CSF sampling We will compare change over time in preHD and control groups and model disease burden influence (an early natural history proxy) within the preHD group. These analyses will incorporate previous baseline measurements (providing three timepoints). We will create a data-driven natural history of pathological changes across the pre-clinical period in HD and estimate longitudinal models of age and CAG-dependence on the outcomes, providing a critical tool to increase power.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 154
Est. completion date December 1, 2025
Est. primary completion date December 1, 2025
Accepts healthy volunteers
Gender All
Age group 18 Years to 47 Years
Eligibility Inclusion Criteria: For the Healthy Control group, participants eligible are persons who meet the following criteria: 1. Are capable of providing informed consent and 2. Are capable of complying with study procedures and 3. Are aged between 18-47 years old and 4. Have no known family history of HD (gene negative); or 5. Have known family history of HD but have been tested for the huntingtin gene CAG expansion and are not at genetic risk for HD (CAG < 36*) (family control or community control) For the Young Adult Premanifest HD group, participants eligible are persons who meet the following criteria: 1. Are capable of providing informed consent and 2. Are capable of complying with study procedures and 3. Are aged between 18-47 years old and 4. Have CAG expansion = 40; 5. New participants must have a DBS <240 Exclusion Criteria: Current use of investigational drugs or participation in a clinical drug trial within 30 days prior to study visit; or b. Current intoxication, drug or alcohol abuse or dependence; or c. If using any antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD, the use of inappropriate (e.g., non-therapeutically high) or unstable dose within 30 days prior to study visit; or d. Significant medical, neurological or psychiatric co-morbidity likely, in the judgment of the Principal Investigator, to impair participant's ability to complete essential study procedures; or e. Predictable non-compliance as assessed by the Principal Investigator; or f. Inability or unwillingness to undertake any of the essential study procedures; or g. Needle phobia: or h. Contraindication to MRI, including, but not limited to, MR-incompatible pacemakers, recent metallic implants, foreign body in the eye or other indications, as assessed by a standard pre-MRI questionnaire;or i. Pregnant (as confirmed by urine pregnancy test); or j. Claustrophobia, or any other condition that would make the subject incapable of undergoing an MRI. For CSF collection: 1. Needle phobia, frequent headache, significant lower spinal deformity or major surgery; or 2. Antiplatelet or anticoagulant therapy within the 14 days prior to sampling visit, including but not limited to: aspirin, clopidogrel, dipyridamole, warfarin, dabigatran, rivaroxaban and apixaban; or 3. Clotting or bruising disorder; or 4. Screening blood test results outside the clinical laboratory's normal range for the following: white cell count, neutrophil count, lymphocyte count, haemoglobin (Hb), platelets, prothrombin time (PT) or activated partial thromboplastin time (APTT); or 5. Screening blood test results for C-reactive protein (CRP)>2Ă— upper limit of normal; or 6. Exclusion during history or physical examination, final decision to be made by the Principal Investigator; including but not limited to: i any reason to suspect abnormal bleeding tendency, e.g. easy bruising, petechial rash; or ii any reason to suspect new focal neurological lesion, e.g. new headache, optic disc swelling, asymmetric focal long tract signs; or iii any other reason that, in the clinical judgment of the operator or the Principal Investigator, it is felt that lumbar puncture is unsafe. For Optional 7T MRI and MEG 1. Contraindication to MRI, including, but not limited to, MR-incompatible pacemakers, recent metallic implants, foreign body in the eye or other indications, as assessed by a standard pre-MRI questionnaire; or 2. Pregnant (as confirmed by urine pregnancy test); or 3. Claustrophobia, or any other condition that would make the subject incapable of undergoing an MRI; or 4. Tattoos that fall above the line defined by the crease of the elbow or on the genitals.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervention
Study is observational

Locations

Country Name City State
United Kingdom University College London London

Sponsors (4)

Lead Sponsor Collaborator
University College, London University of Cambridge, University of Glasgow, University of Iowa

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Brain volume in ml Global and regional measures of brain volume Baseline, 4.5 years, 6 years
Primary Biofluids in grams per litre Blood and CSF measures Baseline, 4.5 years, 6 years
Primary Cognition (raw scores) Cognitive tests including CANTAB and EMOTICOM Baseline, 4.5 years, 6 years
See also
  Status Clinical Trial Phase
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Not yet recruiting NCT04429230 - Non-invasive Brain Stimulation in Huntington's Disease N/A
Recruiting NCT05032196 - Study of WVE-003 in Patients With Huntington's Disease Phase 1/Phase 2
Recruiting NCT03599076 - Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
Terminated NCT04617860 - Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease Phase 1/Phase 2
Completed NCT05748288 - Development of the Virtual Unified Huntington's Disease Rating Scale
Not yet recruiting NCT05360082 - Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
Not yet recruiting NCT04370470 - Development of Assessments for Later Stage HD
Recruiting NCT01834053 - Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea. Phase 1/Phase 2
Completed NCT01357681 - Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study) Phase 2
Completed NCT01458470 - A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease Phase 2
Completed NCT00980694 - Bioavailability of Ubiquinol in Huntington Disease Phase 1
Completed NCT00146211 - TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease Phase 3
Recruiting NCT01412125 - Study of Biomarkers That Predict the Evolution of Huntington's Disease N/A
Completed NCT00075140 - Family Health After Predictive Huntington Disease (HD) Testing Phase 3
Recruiting NCT04818060 - Preparing for Prevention of Huntington's Disease (PREVENT-HD)
Active, not recruiting NCT04698551 - NIPD on cffDNA for Triplet Repeat Diseases
Not yet recruiting NCT04301726 - Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD Phase 1
Completed NCT03421327 - Genetic Risk: Whether, When, and How to Tell Adolescents
Recruiting NCT03296176 - Metabolomic Study in Huntington's Disease (METABO-HD) N/A